All News

Richard Conway Tweet
RichardPAConway
Open label study of only 8 weeks of steroid with tocilizumab for 1 year in GCA. 74% sustained steroid free remission at 1 year. Wow! Needs an RCT. Abstr#1413 #ACR21 @RheumNow https://t.co/c82qGJCFip
TheDaoIndex Tweet
KDAO2011
“NSAIDS are not off the table for older adults!” – Dr @unamakris says use⬇️dose &monitor; GFR may be misleading (toxicity seen w/normal Cr) She’s not a fan of tramadol, but recc topical pain meds, SSRI/NSRI, short-acting⬇️dose opioids when acet & nonpharm Rx fail @rheumnow #ACR21 https://t.co/rLeEagwrQU
Bella Mehta Tweet
bella_mehta
KOA can not only ⬆️ morbidity, it also ⬆️s mortality - long term data from OAI - 5K pts, f/u 9 yrs . Greater KL scores (worse Xrays) - greater mortality! #ACR21 abst#1028 @RheumNow https://t.co/jREmbEN2Ae
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
Clinical Pearl from Dr. @JKolfenbach ⭐️AAV doesn't typically cause hard palate lesions Instead, consider: ➡️Cocaine-induced midline destructive lesion ➤try to send human neutrophil elastase ab (+ in cocaine use but not in AAV) ➡️Malignancy (NK T-cell lymphoma) #ACR21 @RheumNow https://t.co/KIEXgCR23c
David Liew Tweet
drdavidliew
TNFi vs tofacitinib drug survival in RA (based on two Canadian registries, PS adjusted) This seems to be my refrain this ACR: 'TNF inhibitors: let's not forget, they're quite good' #ACR21 ABST1217 @RheumNow @Janetbirdope https://t.co/MyFc6do0JL
Richard Conway Tweet
RichardPAConway
Dr Koster @MdWarrington @AliDuarteMD open label study baricitinib in relapsing GCA. Well-tolerated and allowed GC discontinuation by 24 weeks in most patients. Encouraging, we need an RCT! Abstr#1396 #ACR21 @RheumNow https://t.co/N2h54MHpIq
Dr. John Cush Tweet
RheumNow
FDA Safety Update - Dr. Nadia Habal reviewed approval of Voclosporin, anifrolumab, Avacopen and approved new indications for multiple drugs #ACR21 https://t.co/lAgQ4d0h2m
Dr. John Cush Tweet
RheumNow
FDA safety update: OA Stakeholder Workshop June 2021 - Congrats to FDA & AFfor tackling this LARGE unmet need- difficulty in determining benefit in OA (pain, structure, biomarkers?) -more research needed #ACR21 https://t.co/hCWU8OL0Le
Dr. John Cush Tweet
RheumNow
FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19: 1. RECOVERY - lower mortality 2. EMPACTA - Less progression to mech vent or death 3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej
Dr. John Cush Tweet
RheumNow
FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH
Richard Conway Tweet
RichardPAConway
Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
Mrinalini Dey Tweet
DrMiniDey
"Managing comorbidities can really improve outcomes for our patients" @UnaMakris highlights the bio-psycho-social approach to multicomplexity and multimorbidity in our older patients with RA. #ACR21 @RheumNow https://t.co/TMLqoreogZ
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×